Beta Bionics (BBNX) Registration Filing summary

Company overview and business model

• Designs, develops, and commercializes the iLet Bionic Pancreas, an FDA-cleared, adaptive closed-loop insulin delivery device for people with diabetes, initially focused on type 1 diabetes (T1D).

• iLet autonomously determines all insulin doses using only body weight for initialization, eliminating the need for carb counting or complex settings.

• Commercial launch began in May 2023; initial sales focus on high-volume endocrinology practices, with plans to expand to primary care physicians.

• Revenue model includes device sales and recurring revenue from single-use products (cartridges, infusion sets).

• Pipeline includes a patch pump and a bihormonal iLet (insulin and glucagon), with plans to expand into type 2 diabetes (T2D).

Financial performance and metrics

• Revenue grew from $3.6M for the nine months ended September 30, 2023 to $44.7M for the same period in 2024.

• Net loss was $36.6M for the nine months ended September 30, 2024, compared to $25.3M for the same period in 2023.

• Gross margin improved to 54% for the nine months ended September 30, 2024.

• Installed customer base reached over 15,000 as of year-end 2024, with 67% of new patient starts coming from multiple daily injection (MDI) users.

• Cash, cash equivalents, and short-term investments were approximately $103.6M as of December 31, 2024.

Use of proceeds and capital allocation

• Net proceeds of ~$163M (including concurrent private placement) expected, based on an assumed IPO price of $16.50 per share.

• Proceeds will fund: (i) development and regulatory submissions for the bihormonal iLet and glucagon product, (ii) development and manufacturing of the patch pump, and (iii) expansion of sales/manufacturing infrastructure, working capital, and general corporate purposes.

• Funds are expected to support operations through the first half of 2028.